Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -306.33M | -278.23M | -251.45M | -234.33M | -213.39M |
| Total Depreciation and Amortization | 2.57M | 2.59M | 2.60M | 2.53M | 1.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.17M | 54.31M | 53.43M | 45.60M | 47.35M |
| Change in Net Operating Assets | -2.42M | -8.61M | -1.43M | 4.81M | 2.37M |
| Cash from Operations | -252.02M | -229.94M | -196.85M | -181.39M | -162.41M |
| Capital Expenditure | -1.26M | -1.57M | -2.93M | -3.08M | -2.37M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 255.07M | 217.34M | 245.63M | 168.08M | -170.92M |
| Cash from Investing | 253.80M | 215.77M | 242.70M | 165.00M | -173.29M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.71M | 13.35M | 13.28M | 12.13M | 324.01M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.71M | 13.35M | 13.28M | 12.13M | 324.01M |
| Foreign Exchange rate Adjustments | -595.00K | -535.00K | -1.37M | -1.67M | -269.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.89M | -1.35M | 57.76M | -5.93M | -11.95M |